Liquid Biopsy Market 112017

Liquid Biopsy Market: Rising Cases of Lung Cancer Fuelling Adoption of Liquid Biopsy Across the World: Global Industry Analysis (2012 - 2016) and Opportunity Assessment (2017 - 2027)

Market introduction

Liquid biopsy is an advanced cancer diagnostic test that uses biofluids such as blood, CSF, plasma and urine for detecting cancer. The test can also be used to detect cancer in the early stages. Liquid biopsy is a non-invasive diagnostic test that uses circulating nucleic acids, circulating tumour cells (CTC) and exosomes as a biomarker for the diagnosis of cancer. In the body, the aforementioned biomarkers are released into different body fluids by cancer cells. The test requires blood, urine and cerebral spinal fluid (CSF) samples for diagnosis of various cancers. Among all samples, blood sample is widely used for diagnosis of various cancers such as lung cancer, breast cancer and leukemia. Urine and CSF samples are used for the diagnosis of prostate cancer and brain cancer respectively. In this report, we have considered revenue generation by liquid biopsy test kits and liquid biopsy tests as a whole.

Factors impacting market revenue growth

The demand for liquid biopsy is expected to surge in the coming years owing to the increasing inclination of patients towards non-invasive diagnostic procedures, increasing demand from pharmaceutical and biotechnology companies and rising preference by oncologists for liquid biopsy. Increasing prevalence of lung cancer, growing number of product launches and increasing adoption of personalised medicine is expected to drive revenue growth of the liquid biopsy market.

Market forecast by disease indication

Based on disease indication, the global liquid biopsy market has been segmented into lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, colorectal cancer, leukemia, and others. Clinics in North America are opting for advanced treatment therapies leading to the reduced risk of cancer recurrence. Increasing prevalence of lung and breast cancer is the main reason for the increasing revenue of liquid biopsy tests for lung and breast cancer respectively.

The lung cancer disease indication segment is expected to expand at a significant CAGR during the forecast period due to increasing prevalence of lung cancer around the world. Lung cancer is also anticipated to remain the most attractive disease indication segment in terms of revenue for players in the liquid biopsy market over the forecast period. Breast cancer segment is expected to be the second most lucrative market, with an attractiveness index of 1.6 during the forecast period. The breast cancer segment is expected to register a CAGR of 21.4% in terms of value over the forecast period, followed by the lung cancer segment with a value CAGR of 21.3% for the duration of the assessment period.

global liquid biopsy market

A few key trends governing the global liquid biopsy market

Increasing competition among established players for innovative molecular diagnostic tests in liquid biopsy is expected to drive growth of the global liquid biopsy market over the forecast period. Companies in the liquid biopsy test market are coming up with innovative molecular diagnostic tests, as these tests are gaining traction because of their non-invasive nature as compared to tissue biopsy methods for detecting cancer. Also, these tests provide a less-expensive way to monitor patients throughout the duration of the treatment.

Oncologists are increasingly inclined towards liquid biopsy tests to monitor the disease during the course of therapeutic treatment to detect any genetic mutation. An increasing number of companies in the liquid biopsy market are working to develop a series of tests for monitoring the disease progression. Also, there is an increasing trend for liquid biopsies being used for drug selection at the time of diagnosis, when biopsy tissue is not available or is not accessible. Additionally, liquid biopsies detect drug resistance, screening or early detection of cancer, development of companion diagnostics, determination of prognoses, and assessment of tumour heterogeneity.

Report Description & Structure

This Future Market Insights (FMI) report examines the global liquid biopsy market for the period 2017–2027. The primary objective of the report is to offer insights into developments in the liquid biopsy market that are effecting global businesses and enterprises. This report covers the global liquid biopsy market performance in terms of revenue contribution from various segments. The report also includes in-depth analysis of key trends, drivers, restraints and opportunities, which are likely to influence growth of the global liquid biopsy market. Impact analysis of key growth drivers and restraints are included in this report to better equip clients with crystal clear decision-making insights. The liquid biopsy market report begins with an overview of the market and key definitions. This section also underlines factors influencing revenue growth of the liquid biopsy market along with a detailing of the key trends, drivers, restraints, and opportunities. Furthermore, FMI provides a competitive landscape of the top companies operating in the global liquid biopsy market along with their strategic developments.

Market Segmentation

Biomarker Type

Sample Type

End User

Disease Indication

Region

  • CTCs (Circulating tumour Cells)

  • ctNA (Circulating tumour Nucleic Acids)

  • Exosomes

  • Blood

  • Urine

  • Others (Plasma, Saliva, CSF)

  • Hospitals

  • Cancer Institutes

  • Academic Institutes

  • Diagnostic Centers

  • Lung Cancer

  • Gastrointestinal Cancer

  • Prostate Cancer

  • Breast Cancer

  • Colorectal Cancer

  • Leukemia

  • Others

  • North America

  • Latin America

  • Western Europe

  • Eastern Europe

  • APEJ

  • Japan

  • MEA

The next few sections of the report analyse the global liquid biopsy market based on biomarker type, sample type, disease indication, and end user and present a comprehensive forecast in terms of value for the next 10 years. The next section of the report highlights the growth trends of the liquid biopsy market by region. It provides a market outlook for 2017–2027 and sets the forecast within the context of the global liquid biopsy market. The study discusses key regional trends contributing to the growth of the liquid biopsy market worldwide, as well as analyses the extent to which drivers are influencing this market in each region.

In the final section of the report on the global liquid biopsy market, a detailed competitive landscape is included to provide report audiences with a dashboard view of the leading market players along with information on the key differentiators among the competitor firms. Detailed company profiles presented in this section include company-specific long-term and short-term strategies, key offerings and recent developments in the global liquid biopsy market.

Research Methodology

While forecasting the revenue estimations for the global liquid biopsy market, we have taken into consideration the year-on-year growth to understand the predictability of the market and to identify the right growth opportunities in the global liquid biopsy market. Another key feature of this report is the analysis of the different market segments in terms of absolute dollar opportunity. This is traditionally overlooked while forecasting the market. However, absolute dollar opportunity analysis is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective in the global liquid biopsy market.